Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK012 in Relapsed Small-Cell Lung Cancer
NCT00951613Phase 2Completed
- Sponsor
- Nippon Kayaku Co., Ltd.
- Start
- Jul 2009
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NK012 in small cell lung cancer (SCLC), sponsored by Nippon Kayaku Co., Ltd.. Started Jul 2009; status: completed.
02
Drugs
NK012
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00951613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00951613.